$57.02
+1.39
(+2.5%)▲
Revenue is up for the last 2 quarters, 71.22M → 73.89M (in $), with an average increase of 3.6% per quarter
Netprofit is down for the last 3 quarters, -27.57M → -34.62M (in $), with an average decrease of 12.1% per quarter
2.93%
Downside
Day's Volatility :3.16%
Upside
0.24%
30.71%
Downside
52 Weeks Volatility :35.24%
Upside
6.54%
Period | Glaukos Corp | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 17.79% | -0.3% | -6.7% |
6 Months | 19.45% | -8.8% | -6.2% |
1 Year | 36.25% | -4.2% | -5.1% |
3 Years | 37.73% | 23.0% | 26.9% |
Market Capitalization | 2.7B |
Book Value | $10.61 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -2.82 |
PEG Ratio | 1.64 |
Wall Street Target Price | 58.44 |
Profit Margin | -48.15% |
Operating Margin TTM | -39.82% |
Return On Assets TTM | -7.11% |
Return On Equity TTM | -25.17% |
Revenue TTM | 289.1M |
Revenue Per Share TTM | 6.07 |
Quarterly Revenue Growth YOY | 9.2% |
Gross Profit TTM | 213.9M |
EBITDA | -82.8M |
Diluted Eps TTM | -2.82 |
Quarterly Earnings Growth YOY | 18.96 |
EPS Estimate Current Year | -2.26 |
EPS Estimate Next Year | -1.85 |
EPS Estimate Current Quarter | -0.57 |
EPS Estimate Next Quarter | -0.57 |
What analysts predicted
Upside of 2.49%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 159.3M | ↑ 39.21% |
Net Income | -92.0K | ↓ 102.03% |
Net Profit Margin | -0.06% | ↓ 4.01% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 181.3M | ↑ 13.83% |
Net Income | -13.0M | ↑ 13977.17% |
Net Profit Margin | -7.14% | ↓ 7.08% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 237.0M | ↑ 30.73% |
Net Income | 15.4M | ↓ 219.1% |
Net Profit Margin | 6.51% | ↑ 13.65% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 225.0M | ↓ 5.07% |
Net Income | -120.3M | ↓ 880.26% |
Net Profit Margin | -53.5% | ↓ 60.01% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 294.0M | ↑ 30.7% |
Net Income | -49.6M | ↓ 58.79% |
Net Profit Margin | -16.87% | ↑ 36.63% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 282.9M | ↓ 3.79% |
Net Income | -99.2M | ↑ 100.02% |
Net Profit Margin | -35.07% | ↓ 18.2% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | 73.2M | ↓ 1.97% |
Net Income | -21.9M | ↓ 451.08% |
Net Profit Margin | -29.86% | ↓ 38.2% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 67.7M | ↓ 7.59% |
Net Income | 5.4M | ↓ 124.58% |
Net Profit Margin | 7.94% | ↑ 37.8% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 72.7M | ↑ 7.39% |
Net Income | -45.5M | ↓ 946.87% |
Net Profit Margin | -62.65% | ↓ 70.59% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 71.3M | ↓ 1.95% |
Net Income | -27.6M | ↓ 39.44% |
Net Profit Margin | -38.69% | ↑ 23.96% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 71.2M | ↓ 0.06% |
Net Income | -31.5M | ↑ 14.08% |
Net Profit Margin | -44.17% | ↓ 5.48% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 73.9M | ↑ 3.75% |
Net Income | -34.6M | ↑ 10.06% |
Net Profit Margin | -46.86% | ↓ 2.69% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 165.8M | ↑ 23.42% |
Total Liabilities | 27.6M | ↑ 61.63% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 207.0M | ↑ 24.8% |
Total Liabilities | 33.1M | ↑ 19.82% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 818.4M | ↑ 295.42% |
Total Liabilities | 145.1M | ↑ 338.32% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.0B | ↑ 22.86% |
Total Liabilities | 338.1M | ↑ 132.93% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.0B | ↑ 4.4% |
Total Liabilities | 462.5M | ↑ 36.83% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.0B | ↓ 4.51% |
Total Liabilities | 472.4M | ↑ 2.13% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 1.0B | ↓ 1.36% |
Total Liabilities | 462.5M | ↓ 0.12% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.1B | ↑ 0.23% |
Total Liabilities | 454.5M | ↓ 1.74% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.0B | ↓ 1.98% |
Total Liabilities | 468.8M | ↑ 3.15% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.0B | ↓ 2.21% |
Total Liabilities | 459.9M | ↓ 1.9% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.0B | ↓ 0.6% |
Total Liabilities | 472.4M | ↑ 2.71% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 972.6M | ↓ 2.97% |
Total Liabilities | 464.1M | ↓ 1.76% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 25.5M | ↑ 107.23% |
Investing Cash Flow | -11.7M | ↓ 55.1% |
Financing Cash Flow | 4.7M | ↓ 384.23% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 18.9M | ↓ 26.05% |
Investing Cash Flow | -26.4M | ↑ 125.12% |
Financing Cash Flow | 21.6M | ↑ 362.31% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -369.0K | ↓ 101.96% |
Investing Cash Flow | 43.4M | ↓ 264.49% |
Financing Cash Flow | -9.6M | ↓ 144.7% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -23.0M | ↑ 6129.81% |
Investing Cash Flow | -205.1M | ↓ 572.21% |
Financing Cash Flow | 262.5M | ↓ 2822.05% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 24.7M | ↓ 207.48% |
Investing Cash Flow | -58.2M | ↓ 71.6% |
Financing Cash Flow | 39.3M | ↓ 85.05% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -33.1M | ↓ 233.9% |
Investing Cash Flow | 44.8M | ↓ 176.9% |
Financing Cash Flow | 6.3M | ↓ 84.08% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.7M | ↓ 126.14% |
Investing Cash Flow | -8.9M | ↓ 65.96% |
Financing Cash Flow | 1.6M | ↓ 58.18% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 9.8M | ↓ 310.15% |
Investing Cash Flow | -5.9M | ↓ 33.53% |
Financing Cash Flow | 1.4M | ↓ 12.8% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -12.2M | ↓ 224.88% |
Investing Cash Flow | 9.6M | ↓ 263.3% |
Financing Cash Flow | 106.0K | ↓ 92.48% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -26.5M | ↑ 117.23% |
Investing Cash Flow | 24.4M | ↑ 153.28% |
Financing Cash Flow | 4.2M | ↑ 3867.92% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.1M | ↓ 84.4% |
Investing Cash Flow | 16.7M | ↓ 31.72% |
Financing Cash Flow | 529.0K | ↓ 87.42% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -30.8M | ↑ 643.81% |
Investing Cash Flow | -13.8M | ↓ 183.05% |
Financing Cash Flow | 1.2M | ↑ 117.77% |
Sell
Neutral
Buy
Glaukos Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Glaukos Corp | 17.36% | 19.45% | 36.25% | 37.73% | 47.29% |
![]() Stryker Corporation | -9.47% | 16.08% | 15.77% | 37.64% | 56.01% |
![]() Boston Scientific Corp. | -4.37% | 11.53% | 23.12% | 34.64% | 66.14% |
![]() Edwards Lifesciences Corp. | -7.01% | 5.39% | -19.28% | 9.61% | 77.87% |
![]() Abbott Laboratories | -8.46% | -5.46% | -13.41% | 9.35% | 65.3% |
![]() Medtronic PLC | -9.02% | 4.38% | -17.62% | -15.04% | -4.43% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Glaukos Corp | NA | NA | 1.64 | -2.26 | -0.25 | -0.07 | 0.0 | 10.61 |
![]() Stryker Corporation | 39.68 | 39.68 | 2.85 | 10.16 | 0.16 | 0.06 | 0.01 | 44.51 |
![]() Boston Scientific Corp. | 88.03 | 88.03 | 2.53 | 1.95 | 0.05 | 0.04 | 0.0 | 12.42 |
![]() Edwards Lifesciences Corp. | 33.89 | 33.89 | 3.07 | 2.55 | 0.25 | 0.13 | 0.0 | 9.87 |
![]() Abbott Laboratories | 31.27 | 31.27 | 18.76 | 4.4 | 0.16 | 0.06 | 0.02 | 21.28 |
![]() Medtronic PLC | 28.89 | 28.89 | 3.04 | 5.28 | 0.07 | 0.04 | 0.03 | 38.69 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Glaukos Corp | Buy | $2.7B | 47.29% | NA | -48.15% |
![]() Stryker Corporation | Buy | $103.5B | 56.01% | 39.68 | 13.86% |
![]() Boston Scientific Corp. | Buy | $73.4B | 66.14% | 88.03 | 6.92% |
![]() Edwards Lifesciences Corp. | Buy | $49.7B | 77.87% | 33.89 | 27.07% |
![]() Abbott Laboratories | Buy | $178.9B | 65.3% | 31.27 | 13.98% |
![]() Medtronic PLC | Buy | $108.4B | -4.43% | 28.89 | 12.03% |
BlackRock Inc
Vanguard Group Inc
Wellington Management Company LLP
Brown Capital Management, LLC
Artisan Partners Limited Partnership
State Street Corporation
Glaukos Corp’s price-to-earnings ratio stands at None
Read MoreGlaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
Organization | Glaukos Corp |
Employees | 783 |
CEO | Mr. Thomas William Burns |
Industry | Health Technology |